Every 8-K that Larimar Therapeutics, Inc. (LRMR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow LRMR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LRMR filings page.
Larimar Therapeutics, Inc. (LRMR) appointed John B. Harlow, Jr. as President and Chief Operating Officer effective September 29, 2026. His employment agreement provides an initial annual base salary of $560,000, subject to annual review and adjustment by the Board’s Compensation Committee, a $35,000 cash signing bonus, and eligibility for a target annual bonus equal to 40% of base salary; the 2026 target is prorated. The actual bonus may be more or less based on corporate and/or personal objectives, and payment generally requires continued employment through the executive bonus payment date, subject to specified involuntary-termination provisions.
Larimar granted an option to purchase 800,000 shares at an exercise price equal to the common stock’s closing price on the effective date, plus restricted stock units covering 50,000 shares. The option vests 25% on the first anniversary of the effective date and the remaining 75% in 36 equal monthly installments; the RSUs vest in four equal annual installments beginning on the first anniversary. Both awards require continued service through applicable vesting dates.
Larimar Therapeutics reported second quarter 2026 results and progress for its lead Friedreich’s ataxia program, nomlabofusp. A rolling Biologics License Application seeking accelerated approval is underway after a multidisciplinary FDA pre-BLA meeting in which the agency indicated the existing data package appears capable of supporting submission and reaffirmed its willingness to consider frataxin (FXN) as a novel surrogate endpoint.
Long-term open-label data as of June 2026 showed more than 10,000 doses administered, generally well tolerated with mainly mild-to-moderate injection site reactions, alongside sustained increases in skin FXN levels to ranges seen in asymptomatic carriers and directional improvements in mFARS and other clinical measures versus a FACOMS natural-history cohort. Larimar plans to dose the first patient in a global confirmatory Phase 3 trial in Q3 2026 and targets a potential U.S. launch in mid-2027, if approved. As of June 30, 2026, cash, cash equivalents and marketable securities totaled $156.3 million, with a net loss of $32.8 million for the quarter and projected cash runway into the third quarter of 2027.
Larimar Therapeutics has submitted the first module of a rolling Biologics License Application to the FDA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, after Type B pre-BLA meeting minutes indicated the existing data package appears sufficient for submission and that approval will be a matter of review.
The company reported long-term open-label data showing daily nomlabofusp increased skin frataxin (FXN) from a mean 3.7 pg/µg at baseline to 12.1 pg/µg at one year, with 100% of evaluable participants (9/9 at one year; 3/3 at 18 months) reaching FXN levels comparable to asymptomatic carriers. Clinical outcomes also improved, with a 1.0-point mean mFARS improvement at one year and a 2.3-point improvement at 18 months, versus worsening in a FACOMS natural history reference group, yielding 2.6- and 4.6-point advantages respectively. More than 10,000 doses have been given; daily dosing was generally well tolerated, though anaphylaxis occurred in 10 of 41 participants, all of whom recovered after standard treatment. Larimar expects to complete the rolling BLA in the second half of 2026, start dosing in a global confirmatory Phase 3 trial in Q3 2026, and is targeting a potential U.S. launch around mid-2027 if nomlabofusp is approved.
Larimar Therapeutics, Inc. reported results of its 2026 annual stockholder meeting. As of the March 25, 2026 record date, 103,882,937 common shares were outstanding and entitled to vote.
Stockholders elected Frank Thomas, Carole S. Ben-Maimon, M.D., and Joseph Truitt as Class III directors, approved 2025 executive compensation on an advisory basis, and indicated a preference for holding future say-on-pay votes every year. The Board has decided to follow this annual frequency.
Stockholders ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for 2026 and approved an amendment to increase authorized common shares from 115,000,000 to 215,000,000. They also approved a potential adjournment related to the share increase, although it was ultimately not needed.
Larimar Therapeutics reported first quarter 2026 results while advancing nomlabofusp toward potential approval for Friedreich’s ataxia. The company held $200.4 million in cash, cash equivalents and marketable securities as of March 31, 2026, supporting a projected cash runway into the second quarter of 2027.
Larimar posted a first quarter 2026 net loss of $29.6 million, or $0.31 per common share, with research and development expenses of $25.0 million and general and administrative expenses of $6.1 million. A February underwritten equity offering raised net proceeds of $107.6 million, strengthening the balance sheet.
Regulatory momentum continued as the FDA granted Breakthrough Therapy Designation for nomlabofusp and reaffirmed willingness to consider skin frataxin levels as a surrogate endpoint. Larimar plans a rolling BLA beginning in June 2026 and expects to submit final modules, including CMC, in the second half of 2026, targeting a potential U.S. launch in the first half of 2027 if approved.
Larimar Therapeutics reported a full-year 2025 net loss of $165.7 million, or $2.27 per common share, compared with a net loss of $80.6 million, or $1.32 per share, in 2024. Fourth quarter 2025 net loss was $62.5 million, or $0.73 per common share.
Research and development spending nearly doubled to $154.2 million in 2025, mainly from higher nomlabofusp manufacturing, clinical, and regulatory costs. The FDA granted Breakthrough Therapy Designation for nomlabofusp in Friedreich’s ataxia, and the company plans a June 2026 BLA submission with a potential U.S. launch in the first half of 2027, if approved. Cash, cash equivalents and marketable securities were $136.9 million at December 31, 2025, and pro forma liquidity of $244.5 million including the February 2026 offering is expected to fund operations into the second quarter of 2027.
Larimar Therapeutics, Inc. provides a detailed update on its nomlabofusp program for Friedreich’s ataxia, highlighting regulatory progress, clinical data and funding. Nomlabofusp holds FDA Breakthrough Therapy, Fast Track, Orphan Drug and Rare Pediatric Disease designations, plus PRIME and other expedited designations in Europe and the UK.
The company plans a Biologics License Application seeking accelerated approval in June 2026, supported by an open-label study and a planned global Phase 3 trial using Upright Stability Score and mFARS as primary endpoints. Open-label data show sustained, dose‑dependent increases in skin frataxin, with 100% of 10 evaluated participants above 50% of healthy volunteer levels at 180 days.
Clinical outcomes over one year numerically improved across multiple measures versus a matched FACOMS natural history cohort. Around 8,000 doses have been administered; most adverse events were injection‑site reactions, though 7 of 39 open‑label participants experienced anaphylaxis that resolved with standard treatment. Pro forma cash and investments of $244.5 million as of December 31, 2025 provide an estimated runway into the second quarter of 2027.
Larimar Therapeutics, Inc. entered into an underwriting agreement to sell 20,000,000 shares of common stock at a public offering price of $5.00 per share. The underwriters also received a 30-day option to buy up to 3,000,000 additional shares, which was fully exercised on February 26, 2026.
After underwriting discounts, commissions and estimated expenses, the Company expects net proceeds of approximately $107.6 million from this offering. All shares are being sold by the Company under an existing Form S-3 shelf registration, and the offering is expected to close on February 27, 2026, subject to customary closing conditions.
Larimar Therapeutics announced that the FDA has granted Breakthrough Therapy Designation to nomlabofusp for treating adults and children with Friedreich’s ataxia, recognizing preliminary data that suggest substantial improvement over existing therapy. Following a START pilot program meeting, the FDA signaled continued alignment on using skin frataxin (FXN) as a novel surrogate endpoint to support a Biologics License Application seeking accelerated approval.
The company expects topline data from its ongoing open-label study in Q2 2026, plans to submit the BLA in June 2026, and is targeting a potential U.S. launch in the first half of 2027, if approved. A global confirmatory Phase 3 study is planned to start screening in Q2 2026, with Upright Stability Score as the primary endpoint. Larimar estimates it had $136.9 million in cash and investments as of December 31, 2025, with a projected runway into Q4 2026.
Larimar Therapeutics, Inc. entered into an exchange agreement with Blue Owl Healthcare Opportunities IV Public Investments LP, where the investor will exchange 2,500,000 shares of Larimar common stock for 250,000 shares of Series A convertible preferred stock. Each preferred share is convertible into 10 common shares, but the preferred stock generally carries no voting rights and shares in liquidation proceeds on the same basis as common stock, subject to its ranking terms. In connection with this exchange, Larimar amended the existing designation to increase authorized Series A preferred shares from 250,000 to 500,000. The exchange is expected to close on January 23, 2026, and the preferred shares will be issued without registration under the Securities Act in reliance on Section 3(a)(9).
Larimar Therapeutics, Inc. reported that it had approximately $136.9 million in cash, cash equivalents and marketable securities as of December 31, 2025. This figure was shared in an updated slide presentation posted on the company’s website and is described as unaudited, preliminary and prepared by management, meaning it could change once the company completes its quarter- and year-end financial closing processes.
The company notes that its independent auditor, PricewaterhouseCoopers LLP, has not audited, reviewed, compiled or performed procedures on this preliminary cash figure and provides no assurance on it. Larimar also posted an updated corporate presentation, attached as Exhibit 99.1, which its representatives may use in meetings with investors, analysts and other parties.
Larimar Therapeutics entered an exchange agreement with Blue Owl Healthcare Opportunities IV Public Investments LP, under which the stockholder exchanged 2,500,000 shares of common stock for 250,000 shares of newly designated Series A convertible preferred stock.
Each preferred share is convertible into 10 common shares, subject to a 9.99% beneficial ownership Conversion Blocker, which holders may increase to 19.99% upon 60 days’ notice. The Preferred Stock generally has no voting rights other than as required by law and to approve changes to its terms, participates pari passu with common stock in dividends and liquidation on an as-converted basis, and was issued in reliance on the Section 3(a)(9) exemption from Securities Act registration.
Larimar Therapeutics (LRMR) filed an 8-K announcing an updated corporate presentation posted to its website and furnished as Exhibit 99.1, dated November 10, 2025. The company plans to use the slide deck in meetings with investors, analysts, and other stakeholders.
This is an informational update intended to support outreach and communication. The filing also lists the company’s common stock on the Nasdaq Global Market under the symbol LRMR.
Larimar Therapeutics, Inc. filed an 8-K announcing it furnished a press release with financial results and operational highlights for the third quarter ended September 30, 2025. The press release is attached as Exhibit 99.1.
The information disclosed under Item 2.02, including Exhibit 99.1, is being furnished and is not deemed filed under the Exchange Act.
Larimar Therapeutics (LRMR) reported that it posted an updated corporate slide presentation on its website. The presentation, dated October 14, 2025, is attached as Exhibit 99.1 and incorporated by reference.
Company representatives plan to use the materials in meetings with investors, analysts, and other parties from time to time. This is an informational update with no transaction terms or financial results disclosed in the notice.
Larimar Therapeutics, Inc. (LRMR) filed an 8-K to report a material event: a press release and conference presentation dated September 29, 2025 announcing positive clinical data from its ongoing long‑term open‑label study of nomlabofusp in participants with Friedreich's ataxia. The filing cites positive results at the 25 mg and 50 mg daily subcutaneous dose levels given either by self‑administration or by a caregiver. The press release and presentation are attached as Exhibit 99.1. The filing text is brief and does not disclose detailed efficacy endpoints, participant counts, statistical results, safety findings, or next regulatory steps.
Larimar Therapeutics, Inc. announced its financial results and operational highlights for the second quarter ended June 30, 2025, via a press release furnished on August 14, 2025. The Current Report does not include the numerical results in-line but references that the press release is provided as Exhibit 99.1.
The company also posted an updated corporate slide presentation on its website, furnished as Exhibit 99.2, which company representatives will use in investor and analyst meetings. The filing states the furnished materials are intended to be "furnished" and not "filed" under the Exchange Act.
Larimar Therapeutics, Inc. (Nasdaq: LRMR) filed a Form 8-K to notify investors that an updated corporate slide deck dated June 23, 2025 has been posted to the company’s website and furnished as Exhibit 99.1. The presentation will be used in meetings with investors, analysts and other stakeholders. No new financial results, transactions, or strategic changes were disclosed in the filing. Apart from the presentation and customary Exhibit 104 (Inline XBRL cover page data), the 8-K contains no other material information. The filing is therefore primarily an investor-relations housekeeping action, aimed at ensuring Regulation FD compliance by making the slides publicly available to all market participants.
Larimar Therapeutics (Nasdaq: LRMR) filed a Form 8-K to disclose a regulatory update issued on June 23, 2025. The company released a press release (Exhibit 99.1) stating that the U.S. Food and Drug Administration provided safety-database recommendations and requested additional adult and pediatric data for patients with Friedreich’s Ataxia. To incorporate these data, Larimar has established a “refined timeline” for its forthcoming Biologics License Application (BLA).
The filing notes that management will host a conference call the same day and use a supporting slide deck (Exhibit 99.2) to discuss the regulatory feedback and the updated submission schedule. No financial statements were included; the 8-K is limited to Item 8.01 (Other Events) and Item 9.01 (Exhibits).
For investors, the disclosure is material because FDA feedback can directly influence the timing of commercialization for the company’s lead program targeting Friedreich’s Ataxia. While the agency’s recommendations clarify the data package required, the need to gather and integrate additional safety data could shift the expected BLA submission date, affecting near-term milestones, cash runway assumptions, and valuation timelines.